Patents Examined by Layla D Berry
  • Patent number: 12290527
    Abstract: The present invention relates to methods for reducing soluble P-selectin and major thrombotic events in cancer patients.
    Type: Grant
    Filed: January 12, 2024
    Date of Patent: May 6, 2025
    Assignee: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventors: Jeffrey I. Zwicker, Bruce Furie, Jack Davis Stopa, Robert Flaumenhaft
  • Patent number: 12291583
    Abstract: A carrageenan derivative according to the present disclosure can quickly and easily detect and label the presence of inflammation-related macrophages and, particularly, can accurately and easily identify M1-type macrophages highly associated with early inflammation. In addition, the carrageenan derivative has advantages in that it can be produced easily, environmental pollution is minimized because a small amount of organic solvent is used, and initial cost is low.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: May 6, 2025
    Assignees: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Hong Seog Seo, Yong Jik Lee, Jae Min Jeong, Yun Sang Lee, Ji Yong Park
  • Patent number: 12285035
    Abstract: Oral tablet comprising as active principle an association of dry extracts of turmeric, pomegranate and Boswellia, with colonic release, wherein said release is guaranteed by the presence of a combination of sodium alginate and hydroxypropyl methylcellulose in the relative matrix in which the aforementioned active ingredients are dispersed. This oral tablet, preferably in the form of a food supplement, is employed as co-adjuvant in the treatment and prevention of colonic disorders caused by suspected or confirmed alteration of the inflammatory situation and destabilization of the microbiota.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: April 29, 2025
    Assignee: CHRISTALFARMA S.R.L.
    Inventors: Maria Cristina Del Bono, Francesco Bonomo
  • Patent number: 12286452
    Abstract: The present invention includes novel molecules and methods of using an amphiphilic kanamycin molecule having substitutions at the O-4?, O-6?, or O-4? and O-6? positions having reduced antimicrobial activity for targeting Connexin Hemichannels.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: April 29, 2025
    Assignees: TEXAS TECH UNIVERSITY SYSTEM, UTAH STATE UNIVERSITY
    Inventors: Guillermo A. Altenberg, Cheng-Wei Tom Chang
  • Patent number: 12285437
    Abstract: A pre-prodrug, comprising a drug, e.g., doxorubicin, which has off-target toxicity (e.g., cardiotoxicity) with respect to its antineoplastic activity, and an amine functionality of the drug incorporated into a disubstituted maleimide (DMI). The pre-prodrug may be linked to a targeting or de-targeting agent or a polar modulator, e.g., charged ligand, amino acid, peptide, etc., to increase therapeutic index. The pre-prodrug is hydrolyzed to the prodrug, having a disubstituted maleamic acid (DMA). A polar modulator such as glutamic acid prevents cellular uptake of the prodrug, but not the doxorubicin drug released from the prodrug after dissociation. The prodrug is pH sensitive, and below pH 7.0, tends to cleave to form free drug and cyclized maleic anhydride. Tumor environments tend to be more acidic, e.g., pH 6.8, than cardiac tissue, e.g., pH 7.4, and therefore the heart is spared while the drug is selectively released within a tumor.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: April 29, 2025
    Assignee: The Research Foundation for The State University of New York
    Inventors: Ming An, Lan Yao, Anqi Zhang
  • Patent number: 12280071
    Abstract: A composition has a polyanionic component comprising casein or derivatives thereof, and a polycationic component, which includes chitosan or derivatives thereof. The composition is in the form of nanofibers having a diameter in a range of 20-200 nm. Also disclosed is a process for preparing the composition and a hemostatic article with the composition. A method for inhibiting loss of blood from a hemorrhaging site involves use of the composition and the hemostatic article.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: April 22, 2025
    Assignee: NATIONAL INSTITUTE OF TECHNOLOGY ROURKELA
    Inventors: Devendra Verma, Sabir Hossain
  • Patent number: 12275755
    Abstract: The present invention is directed to a process for purifying natamycin, to an all-trans polyene amphoteric macrolide, to a composition comprising said polyene amphoteric macrolide and to a process for preparing said polyene amphoteric macrolide.
    Type: Grant
    Filed: February 6, 2023
    Date of Patent: April 15, 2025
    Assignee: DSM IP ASSETS B.V.
    Inventors: Alexander Lucia Leonardus Duchateau, Peter Philip Lankhorst, Willebrordus Bernardus Van Scheppingen
  • Patent number: 12269839
    Abstract: Disclosed are P-stereogenic groups that may be used in the synthesis of compounds including stereochemically enriched P-stereogenic phosphorothioates. P-stereogenic groups may be provided in nucleoside phosphoramidites including a sugar bonded to a nucleobase and to a stereochemically enriched phosphoramidite as well as methods of their use and methods of making them.
    Type: Grant
    Filed: January 9, 2023
    Date of Patent: April 8, 2025
    Assignee: SIRIUS THERAPEUTICS, INC.
    Inventors: Sukumar Sakamuri, Curt W. Bradshaw, Dingguo Liu, Laxman Eltepu
  • Patent number: 12268739
    Abstract: Provided herein are Toll-like receptor 2 (TLR2) agonists for use in enhancing human immune response and/or as adjuvants in vaccines. The TLR2 agonists include thiophenes, imidazoles, or phenyl-containing compounds, which may be compounds of Formulae (I), (II), (III), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. The compounds described herein are used as enhancers of an immune response (e.g., innate and/or adaptive immune response), and are useful in treating and/or preventing a disease, as adjuvants in a vaccine for the disease. (e.g., proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: April 8, 2025
    Assignees: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: David J. Dowling, Ofer Levy, Francesco Borriello, David A. Scott, Spencer E. Brightman
  • Patent number: 12263187
    Abstract: The present invention relates to the medical use of polysulfated polysaccharides and compositions thereof for the treatment of disease or disorders associated with bone marrow pathologies in the musculoskeletal system of a mammal. In particular, the invention relates to use of polysulfated polysaccharides, such as pentosan polysulfate, in treatment of bone marrow edema lesions or spinal Modic Endplate Changes as assessed by magnetic resonance imaging (MRI).
    Type: Grant
    Filed: March 2, 2023
    Date of Patent: April 1, 2025
    Assignee: PARADIGM BIOPHARMACEUTICALS LTD
    Inventors: Ravi Krishnan, Paul Rennie
  • Patent number: 12252504
    Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: March 18, 2025
    Assignee: Genzyme Corporation
    Inventors: Luis Z. Avila, Clark Q. Pan, Patrick Finn, John Harrahy, Qun Zhou, Yunxiang Zhu, Paul A. Konowicz, Duncan E. Paterson, Andreas Peer, Joseph P. Kutzko, Michael R. Reardon, James E. Stefano, Xiaoyang Zheng, Robert J. Miller, Lauren Young
  • Patent number: 12239655
    Abstract: Nucleoside compounds, which in some embodiments include an alkynyl substituent at the 4?-position, compositions and methods for treating or preventing HIV and other viral infections, particularly where the virus is present in macrophages, microglia, and primary myeloid cells, and eliminating and/or treating infection in patients infected by these viruses, are disclosed.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: March 4, 2025
    Assignee: Emory University
    Inventors: Raymond F. Schinazi, Franck Amblard, Christina Gavegnano, Bryan Cox, Seema Mengshetti
  • Patent number: 12234302
    Abstract: Disclosed is a method of preparing N-alkylated chitosan derivatives by treating chitosan with an acid and subsequently reacting the chitosan with an alkylating agent in the presence of a base. Also provided are novel N-alkylated chitosan derivatives.
    Type: Grant
    Filed: November 22, 2022
    Date of Patent: February 25, 2025
    Assignee: PRIMEX EHF
    Inventor: Mar Masson
  • Patent number: 12234255
    Abstract: Provided herein are methods of glycosylation in the formation of disaccharides, trisaccharides, and oligosaccharides using fluoroglycosides, silyl ether glycosides and a triaryl borane catalyst.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: February 25, 2025
    Assignee: REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: John Montgomery, Girish Chandra Sati, Joshua Lane Martin
  • Patent number: 12227538
    Abstract: Provided herein are compounds that are glucocorticoid receptor agonists useful for the treatment of autoimmune and inflammatory diseases, processes for preparing these compounds, and pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: March 22, 2022
    Date of Patent: February 18, 2025
    Assignee: Eli Lilly and Company
    Inventors: Donmienne Doen Mun Leung, Jacqueline Mary Wurst, James Andrew Jamison
  • Patent number: 12227534
    Abstract: The invention relates to a method for preparing nicotinamide mononucleotide by using nicotinamide as a raw material, which comprises: in acetonitrile, dichloromethane, 1,2-dichloroethane or liquid sulfur dioxide as a solvent, allowing nicotinamide and tetraacetyl ribose to react as catalyzed by trimethylsilyl trifluoromethanesulfonate or tin tetrachloride, adjusting a pH value thereof to 3-5, adding a sodium methoxide solution thereto to react at ?15° C. to 5° C., adjusting a pH value thereof to 3-5, and subjecting the reaction mixture to microfiltration and nanofiltration using a membrane concentrator, thereby obtain a nicotinamide ribose solution; allowing the nicotinamide ribose solution to react as catalyzed by nicotinamide ribokinase in the presence of Mg ions, ATP and a buffer, thereby obtaining nicotinamide mononucleotide.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: February 18, 2025
    Assignee: BONTAC BIO-ENGINEERING(SHENZHEN) CO., LTD.
    Inventors: Guiping Zhang, Haojie Xu, Qin Wang, Zhang Zhang, Qi Zhang
  • Patent number: 12215123
    Abstract: A cordycepin-based derived compound with an anti-tumor effect, and a structure of the compound is as shown in formula I; a cordycepin derivative and a pharmaceutical composition thereof provided by the invention have a good anti-tumor proliferation effect; compared with a parent drug, the cordycepin derivative has better affinity to cell membranes, so that a half-life period of in-vivo metabolism of the drug is longer, and in-vivo remaining time of the drug is longer; compared with other nucleoside anti-tumor drugs, the cordycepin derivative and the pharmaceutical composition thereof provided by the invention have wider types and action ranges of tumors, have excellent inhibition effects on a gastric cancer, a pancreatic cancer, a liver cancer, a small cell lung cancer, a colorectal cancer, melanoma, an ovarian cancer and the like, and have lower side effects and better curative effects.
    Type: Grant
    Filed: November 9, 2023
    Date of Patent: February 4, 2025
    Assignee: NANJING TECH UNIVERSITY
    Inventors: Hanjie Ying, Tao Shen, Chenglun Tang, Dong Liu, Yong Chen, Chenjie Zhu, Pengpeng Yang, Wei Zhuang
  • Patent number: 12213988
    Abstract: The present disclosure is directed to methods of treating patients with chronic kidney disease (CKD), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin.
    Type: Grant
    Filed: June 14, 2021
    Date of Patent: February 4, 2025
    Assignee: AstraZeneca AB
    Inventor: Anna Maria Langkilde
  • Patent number: 12208111
    Abstract: This disclosure describes the use of azithromycin, roxithromycin, and telithromycin, including derivatives thereof, as senolytic drugs. BrdU was used to induce senescence in model human fibroblast cell lines. Also disclosed are methods for screening compounds for senolytic activity. The SRB assay was used to measure cell viability through protein content. Azithromycin roxithromycin, and telithromycin, clinically-approved pharmaceuticals, were found to be senolytic drugs. However, the closely-related parent compound, erythromycin, showed no senolytic activity. Azithromycin strongly induced both aerobic glycolysis and autophagy in human fibroblasts, but showed bi-phasic effects including on mitochondrial oxygen consumption rates with inhibitory activity at 50 ?M and stimulatory activity at 100 ?M. The xCELLigence real-time assay system showed that azithromycin preferentially targets senescent cells, removing approximately 97% (nearly a 25-fold reduction in senescent cells).
    Type: Grant
    Filed: February 15, 2024
    Date of Patent: January 28, 2025
    Assignee: LUNELLA BIOTECH, INC.
    Inventors: Federica Sotgia, Michael P. Lisanti
  • Patent number: 12202853
    Abstract: The present invention is directed to a process for purifying natamycin, to an epoxide polyene amphoteric macrolide, to a composition comprising said polyene amphoteric macrolide and to a process for preparing said polyene amphoteric macrolide.
    Type: Grant
    Filed: January 19, 2023
    Date of Patent: January 21, 2025
    Assignee: DSM IP ASSETS B.V.
    Inventors: Alexander Lucia Leonardus Duchateau, Peter Philip Lankhorst, Willebrordus Bernardus Van Scheppingen